PEGylated PPI dendritic architectures for sustained delivery of H2 receptor antagonist

被引:73
作者
Gajbhiye, Virendra [1 ]
Kumar, P. Vijayaraj [1 ]
Tekade, Rakesh Kumar [1 ]
Jain, N. K. [1 ]
机构
[1] Dr Hari Singh Gour Vishwavidyalaya, Dept Pharmaceut Sci, Pharmaceut Res Lab, Sagar 470003, MP, India
关键词
PPI dendrimers; PEGylation; Famotidine; Sustained drug delivery; Pharmacokinetic; Pharmacodynamic; BIOMEDICAL APPLICATIONS; POLYAMIDOAMINE DENDRIMERS; STARBURST DENDRIMERS; PAMAM DENDRIMERS; DRUG-DELIVERY; MACROMOLECULES; POLYMERS; CARRIER;
D O I
10.1016/j.ejmech.2008.06.012
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The present study was aimed at synthesizing and exploring the use of long circulating biocompatible PEGylated PPI 5.0G dendrimers for sustained delivery of a H-2 receptor antagonist, Famotidine. PPI 5.0G dendrimers were synthesized and PEGylated using dicarboxylic acid PEG 2000. PEGylation was confirmed by SEC, IR, NMR and MASS spectroscopies. Famotidine was loaded in PFGylated dendritic system and confirmed by IR and differential scanning calorimetry. The PEGylated dendritic system has shown an increased drug loading capacity, a reduced hemolytic toxicity and demonstrated a suitability of PEGylated PPI 5.0G dendrimer for prolonged delivery of Famotidine during in vitro release, in vivo blood level and tissue distribution studies in albino rats. The ulcer index after 5 h of treatment with different formulations was found to be 4.5 +/- 0.28 in case of plain Famotidine solution, while ulcer index was significantly reduced to 0.5 +/- 0.13 in case of Famotidine loaded PEGylated PPI 5.0G dendrimers, indicating sustained release of the drug from drug-PEGylated dendrimer complex. The results suggested that such PEGylated dendrimeric systems could serve as nanoparticulate depot for drugs in body. (C) 2008 Published by Elsevier Masson SAS.
引用
收藏
页码:1155 / 1166
页数:12
相关论文
共 26 条
  • [1] [Anonymous], DRUG DISCOVERY TODAY
  • [2] Poly(amidoamine) (PAMAM) dendritic nanostructures for controlled site-specific delivery of acidic anti-inflammatory active ingredient
    Asthana, A
    Chauhan, AS
    Diwan, PV
    Jain, NK
    [J]. AAPS PHARMSCITECH, 2005, 6 (03)
  • [3] Dendrimers: a new class of nanoscopic containers and delivery devices
    Aulenta, F
    Hayes, W
    Rannard, S
    [J]. EUROPEAN POLYMER JOURNAL, 2003, 39 (09) : 1741 - 1771
  • [4] Dendrimers as potential drug carriers; encapsulation of acidic hydrophobes within water soluble PAMAM derivatives
    Beezer, AE
    King, ASH
    Martin, IK
    Mitchell, JC
    Twyman, LJ
    Wain, CF
    [J]. TETRAHEDRON, 2003, 59 (22) : 3873 - 3880
  • [5] A PEGylated dendritic nanoparticulate carrier of fluorouracil
    Bhadra, D
    Bhadra, S
    Jain, S
    Jain, NK
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 257 (1-2) : 111 - 124
  • [6] Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery
    Calvo, P
    Gouritin, B
    Chacun, H
    Desmaële, D
    D'Angelo, J
    Noel, JP
    Georgin, D
    Fattal, E
    Andreux, JP
    Couvreur, P
    [J]. PHARMACEUTICAL RESEARCH, 2001, 18 (08) : 1157 - 1166
  • [7] Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications
    Esfand, R
    Tomalia, DA
    [J]. DRUG DISCOVERY TODAY, 2001, 6 (08) : 427 - 436
  • [8] Pharmaceutical and biomedical potential of PEGylated dendrimers
    Gajbhiye, Virendra
    Kumar, P. Vijayaraj
    Tekade, Rakesh Kumar
    Jain, N. K.
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (04) : 415 - 429
  • [9] The influence of surface modification on the cytotoxicity of PAMAM dendrimers
    Jevprasesphant, R
    Penny, J
    Jalal, R
    Attwood, D
    McKeown, NB
    D'Emanuele, A
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 252 (1-2) : 263 - 266
  • [10] Kumar P. Vijayaraj, 2007, Current Drug Delivery, V4, P11